Imarike yokulahlekelwa kwesisindo yehlabathi iyaqhubeka ikhula kwaye iphuhlise, kunye nemfuno ekhulayo yezisombululo ezisebenzayo nezikhuselekileyo zokunciphisa umzimba.Omnye wabadlali abakhulu kule marike sisithako sokulahleka kwesisindo semaglutide (CAS 910463-68-2).I-Semaglutide i-glucagon-like peptide-1 (GLP-1) i-receptor agonist esetyenziselwa ukuphatha uhlobo lwe-2 yeswekile kwaye isanda kufumana ingqalelo ekusebenziseni kwayo ekulawuleni ubunzima.
I-Semaglutide isebenza ngokulinganisa iziphumo ze-GLP-1, ihomoni eyenzeka ngokwemvelo emzimbeni onceda ukulawula amanqanaba eswekile yegazi.Kuye kwaboniswa ukunciphisa ukutya kunye nokutya, okukhokelela ekulahlekeni kwesisindo kubantu abanokukhuluphala.Oku kwenza i-semaglutide ibe yinto ekhangayo kwabo bafuna ukufezekisa iinjongo zabo zokunciphisa umzimba.
Imarike yezithako zokulahleka kwesisindo kwihlabathi, kubandakanya i-semaglutide, kulindeleke ukuba ibone ukukhula okubonakalayo kwiminyaka ezayo.Izinto ezinje ngokunyuka kokuxhaphaka kokutyeba, ukukhula kolwazi malunga nemingcipheko yezempilo ehambelana nokutyeba, kunye nemfuno ekhulayo yezisombululo ezisebenzayo zokuncipha kobunzima ziqhuba ukwanda kwemarike.
Iinkampani ezininzi zamachiza zibandakanyeka ngokusebenzayo ekuphuhliseni nasekuthengiseni i-semaglutide yokulawula ubunzima.I-Novo Nordisk, inkokeli yehlabathi jikelele kunyango lwesifo seswekile, iphuhlise inaliti yeveki enye ye-semaglutide ngokukodwa ukulahleka kwesisindo.Inkampani iqhube izilingo ezininzi zeklinikhi ezibonisa ukhuseleko kunye nokusebenza kwe-semaglutide ekukhuthazeni ukulahleka kwesisindo, kunye neziphumo ezikhuthazayo.
Ngo-2021, i-US Food and Drug Administration (FDA) ivume i-semaglutide yokulawula ubunzima bexesha elide kubantu abadala abatyebileyo okanye abatyebileyo abanobunzima obuncinci obunxulumene ne-comorbidity.Oku kuphawula isiganeko esibalulekileyo kwimarike yesithako sokunciphisa umzimba njengoko kukuqala ngqa ukuba i-GLP-1 receptor agonist ivunywe ngokukodwa kulawulo lobunzima.
Ukongeza kwi-United States, amanye amazwe aqaphela amandla e-semaglutide ukujongana nobhubhani wokutyeba.IKhomishoni yaseYurophu inike imvume yokuthengisa kwi-semaglutide yonyango lokukhuluphala, kunye neemvume ezongezelelweyo ezilindelekileyo kwiimarike ezahlukeneyo zamazwe ngamazwe.Ukuqatshelwa ngokubanzi kunye nokwamkelwa kwe-semaglutide yokulahleka kwesisindo ngakumbi iqinisa isikhundla sayo njengomdlali ophambili kwimarike yokulahleka kwesisindo.
Njengoko imarike yehlabathi yezithako zokulahlekelwa kwesisindo iqhubeka ikhula, kubalulekile ukuba iinkampani zonyango zibeke phambili uphuhliso lwezisombululo ezikhuselekileyo nezisebenzayo.I-Semaglutide ibonakalise amandla okukhuthaza ukulahleka kwesisindo kunye nokuphucula impilo ye-metabolic, iyenza ibe kwindawo efanelekileyo ukuhlangabezana nemfuno ekhulayo yeemveliso zokulawula ubunzima.Ngokuqhuba uphando oluqhubekayo kunye neenzame zophuhliso, i-semaglutide kulindeleke ukuba idlale indima ephambili ekujonganeni nobhubhani wokutyeba emhlabeni jikelele kunye nokunceda abantu bafezekise iinjongo zabo zokunciphisa umzimba.
Ixesha lokuposa: Dec-07-2023